BioInvent

One of the largest biotech companies in Sweden is BioInvent. Human antibody libraries made by BioInvent, a biotechnology research and development business founded in 1997, can be used in a variety of different applications. BioInvent provides proteins to pharmaceutical and biotechnology firms, issues licences for the use of its libraries, and forms alliances to research and produce protein-based medicines.

The primary goal of BioInvent is the identification and development of immuno-modulatory antibodies for the treatment of cancer. It advances this goal through partnerships with major pharmaceutical firms, academic research centres, clinical specialist networks, and research foundations. Three products are now in the clinical stages at BioInvent. Its primary programme, BI-1206, is a treatment with a substantial economic prospect and is currently in Phase l/lla for non-Hodgkin lymphoma and chronic lymphatic leukaemia. THR-317, which Oxurion is now developing for diabetic macular edoema, and TB-403, which was developed in conjunction with Oncurious for juvenile brain tumours, are further drugs in the clinical pipeline. The preclinical pipeline of BioInvent includes a partnership with Pfizer to create antibodies that target regulatory T cells as well as myeloid cells linked to tumours.

Founded: 1997
Headquarters: Lund, Sweden
Website: https://www.bioinvent.com/en